"The voice of oncology in Massachusetts."



latest drug updates

  • October 11, 2022 10:36 AM | Katy Monaco (Administrator)

    Lilly USA, LLC is pleased to announce recent major label changes for Retevmo® (selpercatinib, 80 mg and 40 mg capsules). Read press release here

  • August 10, 2022 7:45 AM | Katy Monaco (Administrator)

    NCCN GUIDELINES®: Sacituzumab govitecan-hziy (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Read More

    Learn more about TRODELVY.  Please click to see full Prescribing Information

  • August 01, 2022 9:54 AM | Katy Monaco (Administrator)

    The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis to help people understand their personal risk for breast cancer, when they should begin screening, and how often to screen—in order to detect cancer earlier, for more treatment options and better outcomes. With this information, they are equipped to have more informed conversations with their health care providers and be active decision-makers in their long-term health. Read More

  • June 24, 2022 7:39 AM | Katy Monaco (Administrator)
    The NCCN released new Kidney Cancer guidelines (v1.2023) on June 17th and has elevated Fotivda (tivozanib) to be the only Category 1 recommended regimen, for patients that have failed 2 or more systemic treatments.  More InformationFull Prescribing Information

  • June 10, 2022 1:30 PM | Katy Monaco (Administrator)

    Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported new data further underscoring the significant burden of disease in adults with pyruvate kinase (PK) deficiency regardless of genotype and supporting the potential benefits of treatment with PYRUKYND® for these patients.  Read More.

  • May 26, 2022 5:30 AM | Katy Monaco (Administrator)

    Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma.  Read More.

  • February 14, 2022 4:30 PM | Katy Monaco (Administrator)

    Beginning February 14, 2022, there is a new NDC number for TIBSOVO® (72694-0617-60)*, the old NDC number was 71334-0100-01. SERVIER has new product packaging. The product itself remains the same. Listed below are pictures of the updated product packaging and ordering information.

    Updated Product Ordering Information:



    (ivosidenib tablets)

     250 mg tablet 

     60 tablets/bottle

     10 Digit # 72694-617-60

     (11 Digit # for ordering 72694-0617-60)

    *Per the TIBSOVO® label, the NDC code is 10 digits. We are supplying the 11-digit code for ordering convenience.

    The ordering process for TIBSOVO® remains the same.

    For full prescribing information regarding TIBSOVO®, please visit www.tibsovo.com.

    Servier understands the importance of supplying product to our patients and are committed to ensuring there will be no interruption in supply. We look forward to working with you.
  • February 03, 2022 7:00 AM | Katy Monaco (Administrator)

    The U.S. Food and Drug Administration (FDA) is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two specific types of lymphomas, which are cancers that affect the body’s immune system. Read More.

  • December 08, 2021 7:30 AM | Katy Monaco (Administrator)

    Neulasta® (pegfilgrastim) Onpro® and Neulasta® have an updated Healthcare Common Procedure Coding System (HCPCS) Code and dose descriptor, effective January 1, 2022.

    The UPDATED HCPCS CODE is J2506.  The UPDATED DOSE DESCRIPTOR is Injection, pegfilgrastim, excludes biosimilar, 0.5 mg.  This updated dose descriptor can be billed in multiple units to accommodate a variety of doses. Providers should note the new dose descriptor is now 0.5 mg. Per label, the dose for Neulasta® (pegfilgrastim) is 6 mg. Please accurately report service units when billing.

    Key dates: For dates of service on and after January 1, 2022, providers must use the updated HCPCS Code J2506, and dose descriptor, and discontinue use of the HCPCS Code J2505, as it will no longer be accepted. Providers may only use J2505 for dates of service on or before December 31, 2021.

    Information on the updated code and dose descriptor is summarized in the following attachments:

  • October 20, 2021 3:00 PM | Katy Monaco (Administrator)

    The CMS 2021 ASP Drug Pricing Files for the 4th quarter effective October 1, 2021 through December 31, 2021 reflects updates for ISTODAX® (romidepsin) for injection, for intravenous use.  The update includes the following changes which are effective October 1, 2021:

    • Discontinued HCPCS Code J9315 “Injection, romidepsin, 1mg” on September 30, 2021 and established J9319 “Injection, romidepsin, lyophilized, 0.1mg” on October 1, 2021.
    • Changed the HCPCS Code Dosage from 1mg to 0.1 mg.

    Per CMS, this change in J-code needed to be made because: “A new HCPCS code for Romidepsin Injection, non-lyophilized liquid is needed because it is a single source drug approved under a unique NDC number, and it needs to be differentiated from the existing HCPCS code for a multi-sourced Romidepsin drug in lyophilized powder form."

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software